0001193125-26-156127
SEC filingTango Therapeutics announces departure of CFO Daniella Beckman and appointment of Matthew Gall as new CFO effective April 15, 2026, alongside principal accounting officer and additional leadership changes.
The leadership transition at Tango Therapeutics centers on the CFO role, with Daniella Beckman departing after contributing to the company's IPO and capital raises, and Matthew Gall stepping in with deep biotech finance experience from Kalaris Therapeutics, iTeos Therapeutics, and Sarepta Therapeutics. Gall's compensation package is competitive for a clinical-stage biotech CFO, featuring a $540,000 base salary, 40% target bonus, and substantial equity grants—240,000 stock options vesting over four years and 40,000 RSUs over three years—aligning his incentives with shareholder value creation. Jessica Newcomb's promotion to principal accounting officer from internal SVP Finance ensures continuity in accounting functions. The press release highlights a broader leadership strengthening, including Yen-Ching Chua as Chief Development Operations Officer effective June 1 and Janice Kapty as SVP Corporate Strategy, aimed at accelerating late-stage development of vopimetostat, a PRMT5 inhibitor targeting pancreatic cancer. These changes signal strategic focus on clinical advancement and potential commercialization, critical for investor assessment of execution risk in Tango's pipeline.